Robert L Cook1, Zhi Zhou1, Maria Jose Miguez2, Clery Quiros2, Luis Espinoza3, John E Lewis4, Babette Brumback5, Kendall Bryant6. 1. Department of Epidemiology, University of Florida, Gainesville, Florida. 2. School of Integrated Science and Humanity, Florida International University, Miami, Florida. 3. Department of Public Health & Medical Affairs, Gilead Sciences Inc., Miami, Florida. 4. Department of Psychiatry & Behavioral Sciences, University of Miami School of Medicine, Miami, Florida. 5. Department of Biostatistics, University of Florida, Gainesville, Florida. 6. Alcohol and HIV/AIDS Research, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland.
Abstract
BACKGROUND: Alcohol consumption is associated with poor health outcomes in women living with HIV (WLWH), but whether medication can help to reduce drinking in non-treatment-seeking women or whether reduction in drinking improves HIV outcomes is unclear. We conducted a randomized clinical trial (RCT) of daily oral naltrexone (50 mg) versus placebo in WLWH who met criteria for current unhealthy alcohol use. METHODS:WLWH with current unhealthy alcohol use (>7 drinks/wk or >3 drinks/occasion) were randomly assigned to daily oral naltrexone 50 mg (n = 96) or placebo (n = 98) for 4 months. Drinking outcomes, including the proportion of women who reduced (<unhealthy use criteria) or quit drinking, were assessed at baseline, 2 months, 4 months (end of treatment), and 7 months. In a secondary analysis, HIV viral suppression and changes in CD4 counts were compared in women who did or did not reduce/quit drinking, regardless of intervention assignment. RESULTS: The participants' mean age was 48 years, 86% were African American, and 94% were receiving HIV antiretroviral therapy. Among all participants, 89% and 85% completed the 4-month and 7-month follow-ups, respectively. Participants in both groups substantially reduced drinking over time. At 1 and 3 months, naltrexone was associated with a greater reduction in drinking (p < 0.05), but the proportion who reduced/quit drinking at 4 months (52% vs. 45%, p = 0.36) or 7 months (64% in both groups) was not different. HIV viral suppression at follow-up was significantly better in participants who reduced/quit drinking versus those continuing unhealthy alcohol use at 4 months (72% vs. 53%, p = 0.02) and 7 months (74% vs. 54%, p = 0.02). CONCLUSIONS: Participating in an RCT to reduce drinking was associated with significant drinking reduction regardless of medication assignment, suggesting that nonmedication aspects of research study participation (e.g., repeated assessments and support from research staff) could be important interventions to help reduce drinking outside of research studies. Drinking reduction was associated with improved HIV viral suppression, providing evidence to support recommendations to avoid unhealthy alcohol use among WLWH.
RCT Entities:
BACKGROUND:Alcohol consumption is associated with poor health outcomes in women living with HIV (WLWH), but whether medication can help to reduce drinking in non-treatment-seeking women or whether reduction in drinking improves HIV outcomes is unclear. We conducted a randomized clinical trial (RCT) of daily oral naltrexone (50 mg) versus placebo in WLWH who met criteria for current unhealthy alcohol use. METHODS:WLWH with current unhealthy alcohol use (>7 drinks/wk or >3 drinks/occasion) were randomly assigned to daily oral naltrexone 50 mg (n = 96) or placebo (n = 98) for 4 months. Drinking outcomes, including the proportion of women who reduced (<unhealthy use criteria) or quit drinking, were assessed at baseline, 2 months, 4 months (end of treatment), and 7 months. In a secondary analysis, HIV viral suppression and changes in CD4 counts were compared in women who did or did not reduce/quit drinking, regardless of intervention assignment. RESULTS: The participants' mean age was 48 years, 86% were African American, and 94% were receiving HIV antiretroviral therapy. Among all participants, 89% and 85% completed the 4-month and 7-month follow-ups, respectively. Participants in both groups substantially reduced drinking over time. At 1 and 3 months, naltrexone was associated with a greater reduction in drinking (p < 0.05), but the proportion who reduced/quit drinking at 4 months (52% vs. 45%, p = 0.36) or 7 months (64% in both groups) was not different. HIV viral suppression at follow-up was significantly better in participants who reduced/quit drinking versus those continuing unhealthy alcohol use at 4 months (72% vs. 53%, p = 0.02) and 7 months (74% vs. 54%, p = 0.02). CONCLUSIONS: Participating in an RCT to reduce drinking was associated with significant drinking reduction regardless of medication assignment, suggesting that nonmedication aspects of research study participation (e.g., repeated assessments and support from research staff) could be important interventions to help reduce drinking outside of research studies. Drinking reduction was associated with improved HIV viral suppression, providing evidence to support recommendations to avoid unhealthy alcohol use among WLWH.
Authors: M Alan Brookhart; Sebastian Schneeweiss; Kenneth J Rothman; Robert J Glynn; Jerry Avorn; Til Stürmer Journal: Am J Epidemiol Date: 2006-04-19 Impact factor: 4.897
Authors: Robert L Cook; Kathleen A McGinnis; Jeffrey H Samet; David A Fiellin; Maria C Rodriguez-Barradas; Maria C Rodriquez-Barradas; Kevin L Kraemer; Cynthia L Gibert; R Scott Braithwaite; Joseph L Goulet; Kristin Mattocks; Stephen Crystal; Adam J Gordon; Krisann K Oursler; Amy C Justice Journal: J Gen Intern Med Date: 2009-11-18 Impact factor: 5.128
Authors: Jennifer W Tidey; Peter M Monti; Damaris J Rohsenow; Chad J Gwaltney; Robert Miranda; John E McGeary; James MacKillop; Robert M Swift; David B Abrams; Saul Shiffman; Jean A Paty Journal: Alcohol Clin Exp Res Date: 2007-11-20 Impact factor: 3.455
Authors: Derek D Satre; Varada Sarovar; Wendy Leyden; Charles B Hare; Sheryl L Catz; Kendall J Bryant; Emily C Williams; J Carlo Hojilla; Michael A Horberg; Michael J Silverberg Journal: AIDS Behav Date: 2020-06
Authors: Thibaut Davy-Mendez; Varada Sarovar; Tory Levine-Hall; Alexandra N Lea; Stacy A Sterling; Felicia W Chi; Vanessa A Palzes; Mitchell N Luu; Jason A Flamm; C Bradley Hare; Emily C Williams; Kendall J Bryant; Constance M Weisner; Michael J Silverberg; Derek D Satre Journal: AIDS Behav Date: 2022-09-28
Authors: Rebecca J Fisk; Veronica L Richards; Robert F Leeman; Babette Brumback; Christa Cook; Robert L Cook Journal: Subst Use Misuse Date: 2021-03-26 Impact factor: 2.164
Authors: Natalie E Chichetto; Brittanny M Polanka; Kaku A So-Armah; Minhee Sung; Jesse C Stewart; John R Koethe; E Jennifer Edelman; Hilary A Tindle; Matthew S Freiberg Journal: Curr HIV/AIDS Rep Date: 2020-08 Impact factor: 5.495
Authors: Shantrel S Canidate; Eric W Schrimshaw; Nancy Schaefer; Nioud Mulugeta Gebru; Noelani Powers; Stephen Maisto; Christina Parisi; Robert F Leeman; Sheldon Fields; Robert L Cook Journal: AIDS Behav Date: 2021-11-06
Authors: Veronica L Richards; Zhi Zhou; Yan Wang; Krishna Vaddiparti; Babette Brumback; Robert L Cook Journal: Subst Use Misuse Date: 2021-03-08 Impact factor: 2.164
Authors: Shantrel S Canidate; Christa L Cook; Deepthi Varma; Giselle D Carnaby; Nicole Ennis; Nichole E Stetten; Robert L Cook Journal: BMC Public Health Date: 2020-07-27 Impact factor: 4.135